全文获取类型
收费全文 | 4029010篇 |
免费 | 282673篇 |
国内免费 | 10967篇 |
专业分类
耳鼻咽喉 | 56940篇 |
儿科学 | 132119篇 |
妇产科学 | 113412篇 |
基础医学 | 567359篇 |
口腔科学 | 116001篇 |
临床医学 | 366030篇 |
内科学 | 777044篇 |
皮肤病学 | 94118篇 |
神经病学 | 327885篇 |
特种医学 | 155033篇 |
外国民族医学 | 1425篇 |
外科学 | 602292篇 |
综合类 | 89080篇 |
现状与发展 | 11篇 |
一般理论 | 1645篇 |
预防医学 | 308182篇 |
眼科学 | 93771篇 |
药学 | 297066篇 |
16篇 | |
中国医学 | 8600篇 |
肿瘤学 | 214621篇 |
出版年
2018年 | 43091篇 |
2017年 | 33306篇 |
2016年 | 38140篇 |
2015年 | 43006篇 |
2014年 | 59417篇 |
2013年 | 90474篇 |
2012年 | 119326篇 |
2011年 | 126720篇 |
2010年 | 76566篇 |
2009年 | 72808篇 |
2008年 | 118661篇 |
2007年 | 126674篇 |
2006年 | 128304篇 |
2005年 | 123446篇 |
2004年 | 119891篇 |
2003年 | 115927篇 |
2002年 | 112140篇 |
2001年 | 182343篇 |
2000年 | 186940篇 |
1999年 | 158307篇 |
1998年 | 46725篇 |
1997年 | 41425篇 |
1996年 | 40784篇 |
1995年 | 39319篇 |
1994年 | 36397篇 |
1993年 | 34048篇 |
1992年 | 124873篇 |
1991年 | 121252篇 |
1990年 | 118247篇 |
1989年 | 114748篇 |
1988年 | 105628篇 |
1987年 | 104058篇 |
1986年 | 98359篇 |
1985年 | 94269篇 |
1984年 | 70780篇 |
1983年 | 60345篇 |
1982年 | 36246篇 |
1981年 | 32585篇 |
1979年 | 65176篇 |
1978年 | 46490篇 |
1977年 | 39990篇 |
1976年 | 36961篇 |
1975年 | 40305篇 |
1974年 | 47986篇 |
1973年 | 46091篇 |
1972年 | 43391篇 |
1971年 | 40597篇 |
1970年 | 37878篇 |
1969年 | 36333篇 |
1968年 | 33703篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
91.
OLG München 《MedR Medizinrecht》2006,24(7):431-433
Abstrakt 1. Ein nicht ausgefülltes und nicht unterschriebenes Aufkl?rungsformular in der Krankenakte bildet ein Indiz nicht für, sondern
gegen die Durchführung eines Aufkl?rungsgespr?chs.
2. Wenn vor dem ?rztlichen Eingriff überhaupt keine Aufkl?rung erfolgt, genügt für den Beginn der Verj?hrung eines auf eine
Aufkl?rungspflichtverletzung gestützten Anspruchs die Kenntnis vom Eintritt schwerwiegender Komplikationen. Nicht erforderlich
ist das Wissen, dass sich ein typisches Risiko des Eingriffs verwirklicht hat. 相似文献
92.
Setting goals to maintain hope. 总被引:3,自引:0,他引:3
93.
94.
Zinc sulfate addition to glass-ionomer-based cements: influence on physical and antibacterial properties, zinc and fluoride release. 总被引:5,自引:0,他引:5
Prudencio W R Osinaga Rosa Helena M Grande Rafael Y Ballester Maria Regina L Simionato Célia Regina M Delgado Rodrigues Antonio Muench 《Dental materials》2003,19(3):212-217
OBJECTIVES: The aim of this study is to evaluate the effect of ZnSO(4) addition to a conventional glass ionomer and a resin-modified glass ionomer on solubility, flexural strength, zinc and fluoride (F) release, and Streptococcus mutans growth inhibition. METHODS: 5 or 10% ZnSO(4) was added to Vitremer and Ketac-Fil powders. Solubility test was performed based on ISO 7489. Flexural strength was determined by 3-point bending test based on ISO 4049. Zn release/uptake was determined by atomic emission spectrometry; F release/uptake was measured using a F-specific electrode. Both release measurements were performed for 15 d before and 15 d after recharging. Antibacterial test was conducted according to agar plate methods against S. mutans, by measuring the inhibition halos in 1-h and 15-d specimens. Data were analyzed by ANOVA. RESULTS: Solubility increased with higher ZnSO(4) content, but remained below the ISO 7489 limit. Flexural strength was not affected by ZnSO(4) addition, and Vitremer performed better than Ketac-Fil. The control materials released no zinc. Vitremer with 10% ZnSO(4) released the highest amount of zinc. Fluoride release was similar for Ketac-Fil and Vitremer. In both cases, the highest amounts were released in the first 24 h. The growth inhibition halo of S. mutans was similar for both materials with highest content of ZnSO(4) and occurred only with 1-h specimens. SIGNIFICANCE: Zinc addition decreased microorganisms growth and improved fluoride release, without significantly affecting the materials' flexural strength and solubility. 相似文献
95.
96.
97.
A M Carella 《Leukemia》2003,17(6):1199-1200
98.
Johannes Brettschneider Axel Petzold Sigurd D Süssmuth Georg B Landwehrmeyer Albert C Ludolph Jan Kassubek Hayrettin Tumani 《Movement disorders》2006,21(12):2224-2227
We aimed to evaluate the potential of the cerebrospinal fluid (CSF) axonal damage biomarker NfH(SMI35) in the laboratory-supported differential diagnosis of parkinsonian syndromes. Patients with idiopathic Parkinson's disease (PD; n = 22), multiple-system atrophy (MSA; n = 21), progressive supranuclear palsy (PSP; n = 21), corticobasal degeneration (CBD; n = 6), and age-matched controls (n = 45) were included. CSF levels of NfH(SMI35) were measured using ELISA. Levels of CSF NfH(SMI35) were elevated in PSP compared to PD and controls (P < 0.05 each). They were also significantly higher in MSA than in PD and controls (P < 0.05 each). NfH(SMI35) differentiated PD from PSP with a sensitivity of 76.5% and a specificity of 94.4%. Axonal damage as measured by CSF NfH(SMI35) is most prominent in the more rapidly progressive syndromes PSP and MSA as compared to PD or CBD. CSF NfH(SMI35) may therefore be of some value for the laboratory-supported differential diagnosis of atypical parkinsonian syndromes. 相似文献
99.
S Dvorakova E Vaclavikova A Ryska J Cap P Vlcek J Duskova D Kodetova V Holub Z Novak B Bendlova 《Experimental and clinical endocrinology & diabetes》2006,114(4):192-196
Medullary thyroid carcinoma (MTC) is a rare form of thyroid cancer representing about 10% of all thyroid malignancies. It occurs mostly as a sporadic tumor or in association with autosomal dominant inherited cancer syndromes--multiple endocrine neoplasia (MEN) types 2A and 2B and familial MTC. Germline mutations in exons 8, 10, 11, 13, 14, 15 and 16 of the RET proto-oncogene are found in most of the familial cases. There are only a few published data reporting multiple germline mutations in the RET proto-oncogene. We have detected double germline mutations in 2 different exons on the same RET allele in two MEN 2 families. In the MEN 2A family, double germline mutation in exons 10 (Cys620Phe) and 13 (Tyr791Phe) was detected. In the MEN 2B family, beside the classical germline mutation in exon 16 (Met918Thr) a second germline mutation in exon 13 (Tyr791Phe) was found. This study revealed that MEN 2 syndromes can also be caused by double germline mutations in the RET proto-oncogene and these families can be added to small worldwide cohort of families with multiple germline mutations. 相似文献
100.
The aim of the study was to evaluate differences in the relationship between peripheral diabetic neuropathy and microvascular reactivity in type 1 and type 2 diabetic patients. Twenty-eight type 1 and 37 type 2 diabetic patients were included in the study. Control groups consisted of 18 and 25, age and body mass index matched healthy persons. The presence of peripheral neuropathy was estimated by vibration perception threshold higher than 20 V evaluated by biothesiometry. Microvascular reactivity was examined by laser doppler fluxmetry using postocclusive reactive hyperemia and thermal hyperemia. The following variables of vascular reactivity were examined: peak flow after occlusion as a difference between maximal and basal perfusion (PORH (max)), mean velocity increase during postocclusive hyperemia (PORH (max)/t (1)), peak flow during thermal hyperemia (TH (max)) and the mean velocity increase in the perfusion during thermal hyperemia (TH (max)/t (2)). These parameters are expressed in perfusion units (PU) or in perfusion units per second (PU . s (-1)). The microvascular reactivity in type 1 diabetic patients without evidence of peripheral neuropathy was comparable with that in healthy persons and it was significantly higher than in type 1 diabetic patients with peripheral neuropathy in all tested parameters (PORH (max): 64 [40; 81] PU vs. 24 [17; 40] PU, p < 0.001, PORH (max)/t (1): 5.41 [2.69; 8.18] PU/s vs. 1.21 [0.69; 2.5] PU/s, p < 0.001, TH (max): 105 [77; 156] PU vs. 56 [46; 85] PU, p < 0.001 and TH (max)/t (2): 2.48 [1.67; 3.33] PU/s vs. 0.87 [0.73; 1.06] PU/s, p < 0.001). On the contrary, no difference in the microvascular reactivity parameters was found between type 2 diabetic patients with and without neuropathy (PORH (max): 48 [30; 60] PU vs. 49 [36; 57] PU, NS, PORH (max)/t (1): 3.46 [2.15; 5.19] PU/s vs. 3.29 [2.45; 4.8] PU/s, NS, TH (max): 95 [78; 156] PU vs. 97 [73; 127] PU, NS and TH (max)/t (2): 1.45 [0.95; 2.84] PU/s vs. 1.37 [1.12; 1.95] PU/s, NS). In both these groups microvascular reactivity was comparable with that estimated in the age and BMI matched healthy persons. An inverse relationship was observed between microvascular reactivity and vibratory perception threshold in type 1 diabetic patients, but it was not true in type 2 diabetic patients. We suppose that the pathogenesis of neuropathy and impaired microvascular reactivity may be differently influenced by metabolic factors in type 1 and type 2 diabetic patients. 相似文献